GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting
June 3, 2013
/PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) today reported that results of a new study were presented on
Sunday, June 2
, during the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting held in
. The abstract of the presentation entitled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts)" (Abstract #3639), by Dr.
Daniel J. Sargent
, Professor of Biostatistics and Oncology at Mayo Clinic, and colleagues, is now available on the American Society of Clinical Oncology's website,
"We believe this new study provides very strong evidence that measuring the expression level of GCC in lymph nodes is central to improved staging for patients diagnosed with node-negative colon cancer." said Dr
, President and Chief Medical Officer of DiagnoCure. "Prognostic risk stratification in stage II colon cancer remains a very clinically important issue and the ability of our Previstage
GCC test to predict recurrence independently of traditional histopathology risk factors should have significant clinical impact for physicians treating colon cancer and their patients."
The VITAR retrospective study (Validating Indicators To Associate Recurrence) had been designed to assess the relationship between GCC gene expression in formalin fixed (FFPE) LNs and time to recurrence (TTR) in stage II Colon Cancer patients not treated with adjuvant chemotherapy. The second phase (called VITAR II), the results of which were presented at the 2013 ASCO meeting, focused on the positive lymph node ratio (LNR), defined as the number of nodes in which cancer cells were identified with the GCC assay, divided by the total number of nodes examined to provide recurrence risk stratification. On a validation set including 463 untreated stage II (T3N0) colon cancer patients from North American and European sites, the study showed that molecular staging based on GCC LNR status was able to predict higher recurrence risk for 195 patients (42%) treated by surgery alone. All patients had not been treated with adjuvant chemotherapy mainly because their lymph nodes appeared cancer-free by examination under the microscope, yet 10% of them had a disease recurrence or died from cancer afterwards.